Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention
Clinical Infectious Diseases · 05.12.2023 · 77 (Supplement_6) · S447-S454
DOI: 10.1093/cid/ciad639 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Infectious Diseases, online erschienen am 05.12.2023. Verfasst von Thomas Lavoie und 2 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Seres and Ferring.
Themen: Nosokomiale Infektionen
Abstract (Originalsprache)
The profound impact of the human microbiome on health and disease has captivated the interest of clinical and scientific communities. The human body hosts a vast array of microorganisms collectively forming the human microbiome, which significantly influences various physiological processes and profoundly shapes overall well-being. Notably, the gut stands out as an exceptional reservoir, harboring the most significant concentration of microorganisms, akin to an organ in itself. The gut microbiome's composition and function are influenced by genetics, environment, age, underlying conditions, and antibiotic usage, leading to dysbiosis and pathogenesis, such as Clostridioides difficile infection (CDI). Conventional CDI treatment, involving antibiotics like oral vancomycin and fidaxomicin, fails to address dysbiosis and may further disrupt gut microbial communities. Consequently, emerging therapeutic strategies are focused on targeting dysbiosis and restoring gut microbiota to advance CDI therapeutics. Fecal microbiota transplantation (FMT) has demonstrated remarkable efficacy in treating recurrent CDI by transferring processed stool from a healthy donor to a recipient, restoring gut dysbiosis and enhancing bacterial diversity. Moreover, 2 newer Food and Drug Administration (FDA)-approved live biotherapeutic products (LBP), namely, Fecal Microbiota Live-JSLM and Fecal Microbiota Spores Live-BRPK, have shown promise in preventing CDI recurrence. This review explores the role of the gut microbiota in preventing and treating CDI, with an emphasis on gut-based interventions like FMT and fecal microbiota-based products that hold potential for gut restoration and prevention of CDI recurrence. Understanding the microbiome's impact on CDI prevention and treatment offers valuable insights for advancing future CDI therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA.
- College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA.
- Center of Innovation in Long-Term Support Services, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA.
- Warren Alpert Medical School of Brown University, Division of Infectious Diseases, Providence, Rhode Island, USA.
- School of Public Health, Brown University, Providence, Rhode Island, USA.
ORCID-Profile: Kerry L LaPlante
Förderung
- Seres and Ferring
Zitieren
APA
Lavoie, T., Appaneal, H. J., & LaPlante, K. L. (2023). Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention. Clinical Infectious Diseases, 77(Supplement_6), S447-S454. https://doi.org/10.1093/cid/ciad639
Vancouver
Lavoie T, Appaneal HJ, LaPlante KL. Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention. Clinical Infectious Diseases. 2023;77(Supplement_6):S447-S454. doi:10.1093/cid/ciad639
BibTeX
@article{Lavoie2023,
author = {Lavoie, Thomas and Appaneal, Haley J and LaPlante, Kerry L},
title = {Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {77},
number = {Supplement_6},
pages = {S447--S454},
doi = {10.1093/cid/ciad639}
}
EUVIMED